What are the main active compounds in andiroba oil and what do they do?

Andiroba oil's primary bioactives are tetranortriterpenoid limonoids, especially gedunin, 7-deacetoxy-7-oxogedunin (found at 2.48 mg/g in seed extracts), 6α-acetoxygedunin, and carapanosins A/B/C. These compounds inhibit NF-κB signaling and suppress nitric oxide production in inflammatory macrophages—carapanosin C achieves this with an IC₅₀ of 13.7 μM—while gedunin also reduces intracellular triglycerides more potently than metformin at 3–30 μM in hepatocyte models.

Is andiroba oil safe to take orally or use topically?

Preclinical safety data show no cytotoxicity or genotoxicity in mouse bone marrow at oral doses of 250–1,000 mg/kg, and isolated limonoids are non-toxic to normal macrophages at therapeutic concentrations of 3–10 μM. However, no human safety trials exist, drug interactions have not been studied, and use during pregnancy or lactation cannot be considered established as safe; individuals on medications—especially chemotherapeutics or immunosuppressants—should seek medical advice before oral use.

Has andiroba been tested in human clinical trials?

As of the available published literature, no registered human clinical trials have been completed for Carapa guianensis seed oil or its isolated limonoids. All efficacy evidence comes from in vitro cell assays and rodent in vivo studies, meaning therapeutic claims—though mechanistically plausible—remain unvalidated in humans and should be interpreted with caution.

What is the traditional Amazonian use of andiroba oil?

Indigenous and ribeirinho communities across the Amazon have used andiroba oil for centuries as a topical treatment for inflammation, joint and muscle pain, skin infections, wound healing, and as an insect repellent and antimalarial. The oil is typically cold-pressed or extracted by boiling seeds and skimming the solidified fat, and it remains one of the most commercially traded medicinal oils in Amazonian markets today.

What dose of andiroba oil is effective for anti-inflammatory or hepatoprotective effects?

In rodent preclinical studies, oral administration of andiroba limonoid fractions at 25 mg/kg provided statistically significant hepatoprotection against D-galactosamine/LPS-induced liver injury; no equivalent human dose has been validated. Traditional oral use in Amazonian communities typically involves 1–5 mL of crude seed oil daily, but no standardized supplement dosage or clinical guideline exists for humans, and bioavailability data needed to extrapolate from animal doses are lacking.

Does andiroba oil interact with common medications like anti-inflammatory drugs or blood thinners?

While andiroba's limonoids inhibit inflammatory pathways similar to some pharmaceutical anti-inflammatories, direct drug interaction studies are limited. Concurrent use with blood thinners or NSAIDs should be discussed with a healthcare provider due to potential additive effects, particularly given andiroba's mechanisms of action on immune and inflammatory signaling. No major adverse interactions have been documented in the available literature, but caution is warranted with immunosuppressants.

Is andiroba oil safe to use during pregnancy or for nursing mothers?

There is insufficient safety data on andiroba use during pregnancy or lactation, and it is not currently recommended for these populations. Traditional Amazonian use does not establish safety in clinical settings, and the potent immune-modulating effects of its limonoids make cautious avoidance prudent until human pregnancy studies are conducted. Women of childbearing age should consult a healthcare provider before use.

How does the bioavailability of andiroba oil differ between liquid extract, capsule, and topical forms?

Andiroba's limonoids are lipophilic compounds with generally poor water solubility, making oil-based delivery forms (liquid extracts or capsules with lipid matrices) theoretically more bioavailable than aqueous formulations. Topical application bypasses first-pass hepatic metabolism and delivers active compounds directly to tissue, though skin penetration varies based on formulation and carrier vehicles. Standardized extract forms with quantified limonoid content offer more predictable bioavailability than whole oil preparations.

Andiroba

Andiroba seed oil contains a suite of tetranortriterpenoid limonoids—most notably gedunin, carapanosins A/B/C, and 7-deacetoxy-7-oxogedunin—that suppress inflammatory mediators by inhibiting NF-κB signaling and blocking nitric oxide (NO) production in activated macrophages. In preclinical models, carapanosin C inhibits NO with an IC₅₀ of 13.7 μM, gedunin-type limonoids reduce hepatic triglyceride accumulation more potently than metformin at 3–30 μM, and oral administration at 25 mg/kg confers significant hepatoprotection against D-GalN/LPS-induced liver injury in rodents.

Category: Amazonian Evidence: 1/10 Tier: Preliminary

Origin & History

Carapa guianensis is a large canopy tree native to the Amazon Basin, occurring across Brazil, Peru, Colombia, Venezuela, and the Guianas, typically growing in flooded várzea forests and along riverbanks at low elevations. The tree thrives in humid tropical climates with high rainfall and produces large fruits containing seeds from which the commercially significant andiroba oil is cold-pressed. Indigenous Amazonian communities have cultivated and harvested andiroba as a non-timber forest product for centuries, making it one of the most economically important medicinal oils in the region.

Historical & Cultural Context

Andiroba oil has been central to Amazonian ethnomedicine for hundreds of years, used by indigenous peoples including the Tikuna, Kayapó, and ribeirinho communities of Brazil for treating fever, inflammation, arthritis, skin infections, wounds, and as a topical anti-malarial and insect repellent. The oil is extracted by boiling seeds and allowing the fat to solidify, or by cold-pressing, and it remains one of the top-selling medicinal oils in Amazonian markets, traded both locally and internationally as a component of cosmetic and pharmaceutical products. Colonial-era naturalists and later 19th-century botanical explorers documented andiroba's widespread use across Brazil, Venezuela, and the Guianas, noting its distinctive bitter taste—attributable to its high limonoid content—which distinguishes it from edible oils. Contemporary ethnobotanical surveys confirm that andiroba oil's multi-use profile (anti-inflammatory, antimicrobial, pesticidal, wood preservative) has made it an important agroforestry product supporting sustainable livelihoods in extractivist communities throughout the Amazon.

Health Benefits

- **Anti-Inflammatory Activity**: Limonoids including gedunin and carapanosins A/B/C inhibit NO production in LPS-stimulated RAW264.7 macrophages and suppress NF-κB-dependent cytokines (TNF-α, IL-1β, IL-5, CCL11/eotaxin), collectively reducing inflammatory cell infiltration by eosinophils, T lymphocytes, and mast cells.
- **Hepatoprotection**: Gedunin, 7-deacetoxy-7-oxogedunin, and 6α-acetoxygedunin administered orally at 25 mg/kg protect rodent livers from D-galactosamine/LPS-induced acute injury, with gedunin-class limonoids also reducing intracellular triglyceride accumulation at concentrations as low as 3 μM—surpassing the efficacy of metformin in vitro.
- **Antigenotoxic and Chemoprotective Effects**: Andiroba seed oil at 250–1,000 mg/kg showed no intrinsic genotoxicity or cytotoxicity in mouse bone marrow assays and significantly modulated DNA damage induced by mitomycin C and cyclophosphamide, suggesting a protective role during chemotherapeutic exposure.
- **Antimalarial Potential**: Andirolide H, a limonoid isolated from Carapa guianensis, demonstrated antimalarial activity against Plasmodium falciparum with an EC₅₀ of 4.0 × 10⁻⁶, supporting the traditional use of andiroba oil in malaria-endemic Amazonian communities.
- **Cytotoxic Activity Against Cancer Cell Lines**: Carapanolide A exhibited cytotoxicity against L1210 murine leukemia cells with an IC₅₀ of 8.7 μM, while carapanolide F showed IC₅₀ of 15.9 μM and gedunin inhibited P388 leukemia cells at IC₅₀ of 16.0 μM, indicating broad limonoid-mediated cytotoxic selectivity in vitro.
- **Antimicrobial and Wound-Healing Support**: Traditional topical application of andiroba oil leverages its limonoid and fatty acid content (particularly oleic acid up to 8.3%) to inhibit microbial growth and support dermal wound repair, consistent with in vitro antimicrobial findings, though controlled clinical data remain absent.
- **Triglyceride-Lowering and Metabolic Effects**: Gedunin-type limonoids reduce intracellular triglyceride levels in hepatocyte models at 3–30 μM with potency exceeding metformin, hinting at potential metabolic utility for fatty liver conditions that warrants further investigation in structured clinical trials.

How It Works

Andiroba's primary bioactive limonoids—particularly gedunin and carapanosins A/B/C—suppress the NF-κB transcription factor pathway, thereby downregulating the gene expression of inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokines including TNF-α, IL-1β, IL-5, and the chemokine CCL11/eotaxin in LPS-activated macrophages and eosinophilic inflammatory models. At the cellular level, carapanosin C achieves NO inhibition with an IC₅₀ of 13.7 μM, and compound 20 (a structurally related limonoid) inhibits NO at IC₅₀ of 5.9 μM without cytotoxicity at 3–10 μM, indicating a favorable therapeutic window. For hepatoprotection, gedunin-class limonoids appear to modulate lipid metabolism pathways—potentially involving AMP-activated protein kinase (AMPK) or PPARα, though precise receptor targets are not yet fully elucidated—resulting in intracellular triglyceride clearance superior to metformin at equimolar concentrations. Cytotoxic activity against leukemia cell lines likely involves disruption of Hsp90 chaperone function (a known gedunin target) and induction of apoptotic cascades, while antigenotoxic effects may reflect upregulation of DNA repair enzymes and antioxidant defense systems in somatic cells.

Scientific Research

The evidence base for Carapa guianensis consists entirely of in vitro cell culture experiments and in vivo rodent studies; no registered human clinical trials have been published as of the available literature. In vitro studies have characterized at least 23 isolated limonoids for NO inhibitory potency in RAW264.7 macrophages, cytotoxicity against L1210 and P388 leukemia lines, and antimalarial activity against Plasmodium falciparum, providing quantified IC₅₀ and EC₅₀ values across a range of compounds. In vivo rodent studies have demonstrated hepatoprotective effects at oral doses of 25 mg/kg against D-GalN/LPS challenge, and antigenotoxic activity of whole seed oil at 250–1,000 mg/kg in mouse bone marrow micronucleus assays without observed toxicity. While the preclinical data are mechanistically coherent and the phytochemical characterization via ESI-MS, GC-MS, and NMR is rigorous, the absence of pharmacokinetic data, bioavailability studies, and any phase I–III human trials represents a significant translational gap.

Clinical Summary

No human clinical trials have been conducted on Carapa guianensis extracts, seed oil, or isolated limonoids as of the available published record, meaning all efficacy claims derive exclusively from preclinical models. Rodent hepatoprotection studies at 25 mg/kg (oral) and in vitro macrophage assays measuring NO, cytokine secretion, and cell viability constitute the primary outcome data. Effect sizes in cell-based systems are pharmacologically meaningful—gedunin outperforming metformin on triglyceride reduction at 3–30 μM, carapanolide A achieving sub-10 μM cytotoxicity—but interspecies translation to humans remains unvalidated. Confidence in clinical recommendations is therefore low, and andiroba's therapeutic potential, while biologically plausible and ethnobotanically supported, must be regarded as hypothesis-generating pending controlled human studies.

Nutritional Profile

Andiroba seed oil is composed predominantly of mixed triglycerides with a fatty acid profile rich in oleic acid (monounsaturated, up to 8.3% reported in some fractions, with overall oleic content typically 40–55% of total fatty acids in full oil), palmitic acid (~25–30%), stearic acid (~8–12%), and linoleic acid (~5–10%), providing a lipid composition favorable for membrane fluidity and skin barrier function. The unsaponifiable fraction, constituting 2–5% of the oil, is pharmacologically significant and contains tetranortriterpenoid limonoids (gedunin and analogs at concentrations such as 2.48 mg/g for 7-deacetoxy-7-oxogedunin in seed extracts), pentacyclic triterpenoids (lupeol, α-amyrin, β-amyrin), phytosterols, alkaloids, coumarins, and flavonoids. The seed itself also contains proteins and carbohydrates as structural components, but these are largely separated during oil extraction. Bioavailability of limonoids from oral oil ingestion has not been quantified in human studies; lipid solubility of gedunin and related compounds suggests potential absorption via lymphatic chylomicron pathways, though first-pass hepatic metabolism and bioavailability remain uncharacterized.

Preparation & Dosage

- **Cold-Pressed Seed Oil (Topical)**: Applied directly to skin for inflammation, wounds, insect repellency, and pain relief; no standardized dose, traditionally used liberally as needed by Amazonian communities.
- **Cold-Pressed Seed Oil (Oral, Traditional)**: Consumed in small quantities (typically 1–5 mL/day) in traditional Amazonian practice; no clinically validated oral dose established.
- **Limonoid-Enriched Extract (Oral, Preclinical Reference Dose)**: 25 mg/kg body weight orally in rodent hepatoprotection studies; human equivalent dose (HED) approximation ~2–4 mg/kg, but not validated in humans.
- **Whole Oil Antigenotoxic Range (Preclinical)**: 250–1,000 mg/kg in mouse bone marrow studies showed safety and antigenotoxic effect; direct human extrapolation is not supported without pharmacokinetic data.
- **Standardization**: No commercially standardized supplement form exists; research fractions are characterized by limonoid content via ESI-MS and NMR, but no standardization percentage is industry-established.
- **Timing Notes**: Traditional topical use is applied post-injury or daily for chronic conditions; oral traditional use is typically with meals; no clinical timing data exist.

Synergy & Pairings

Andiroba's NF-κB-inhibiting limonoids may act synergistically with other natural NF-κB modulators such as curcumin (from Curcuma longa) or boswellic acids (from Boswellia serrata), potentially enabling lower doses of each to achieve equivalent or superior anti-inflammatory suppression through complementary pathway interference at different nodes of the inflammatory cascade. The oleic acid-rich fatty acid matrix of andiroba oil may enhance the oral bioavailability of co-administered fat-soluble bioactives (e.g., vitamin D, coenzyme Q10, or other limonoids) by facilitating lymphatic absorption via chylomicron incorporation. In traditional Amazonian practice, andiroba is frequently combined with copaiba oil (Copaifera spp., rich in β-caryophyllene) for topical anti-inflammatory and wound-healing applications, a pairing that may produce additive effects through simultaneous CB2 receptor agonism (copaiba) and iNOS suppression (andiroba).

Safety & Interactions

Andiroba seed oil demonstrated no cytotoxicity or genotoxicity in mouse bone marrow at oral doses of 250–1,000 mg/kg, and isolated limonoids show selective toxicity toward cancer cell lines with a non-toxic window in normal macrophages at 3–10 μM, suggesting a reasonable preclinical safety profile. No human adverse event data, drug interaction studies, or formal toxicology trials (subchronic or chronic) have been published, meaning potential interactions with anticoagulants, hepatotoxic drugs, immunosuppressants, or chemotherapeutic agents cannot be ruled out—particularly given gedunin's known Hsp90 inhibitory activity and the oil's documented modulation of cyclophosphamide genotoxicity. Contraindications during pregnancy and lactation have not been evaluated in any controlled study; traditional use does not preclude risk, and caution is warranted given the potent biological activity of limonoids on cell proliferation and immune function. Maximum safe doses for human oral consumption have not been established, and individuals with liver disease, immune disorders, or those undergoing chemotherapy should consult a healthcare provider before use.